FINWIRES · TerminalLIVE
FINWIRES

Astellas Pharma's Profit Surges 475% in Fiscal 2025

By

Astellas Pharma's (TYO:4503) profit attributable to owners of the parent soared 475% to 291.5 billion yen in fiscal year 2025 from 50.7 billion yen a year earlier.

The pharmaceutical firm's earnings per share increased to 162.22 yen from 28.24 yen a year ago, according to a Tokyo bourse filing on Friday.

Revenue jumped 12% to 2.139 trillion yen in the year ended March 31 from 1.912 trillion yen in the prior year.

During the year, Astellas Pharma booked a 16.4 billion yen impairment loss for intangible assets related to AT132 following a halt in the gene therapy program and a redeployment of resources to ASP2957, the company said in a separate disclosure.

The Japanese firm declared a final dividend of 39 yen per share for fiscal 2025, payable from June 3.

For fiscal 2026, the company expects attributable profit of 300 billion yen, basic EPS of 167.46 yen, and revenue of 2.220 trillion yen.

Astellas plans to pay interim and year-end dividends of 40 yen per share each for the year, which is higher than the amount paid in the year-ago period.

Related Articles

Asia

Fadu Returns to Profit in Q1 as Sales Triple; Shares Jump 14%

Fadu (KOSDAQ:440110) posted first-quarter net income of 10.2 billion won, rebounding from a net loss of 12.1 billion won a year earlier, according to a Monday filing with the Korea Exchange.The South Korean chipmaker's sales revenue surged 210% year over year to 59.5 billion won from 19.2 billion won.Shares of Fadu jumped nearly 14% in recent trade.

KOSDAQ:440110
Asia

ASX Biggest Losers

Here are the 10 ASX-listed companies with the biggest losses on Monday.Wisetech (ASX:WTC): -3%, AU$42.79NexGen Energy (ASX:NXG): -3%, AU$17.26Telix Pharmaceuticals (ASX:TLX): -2%, AU$14.47Cochlear (ASX:COH): -2%, AU$94.76Paladin Energy (ASX:PDN): -2%, AU$12.28Origin Energy (ASX:ORG): -2%, AU$12.44EVT (ASX:EVT): -2%, AU$12.44Tuas (ASX:TUA): -2%, AU$5.97Ramsay Health Care (ASX:RHC): -2%, AU$39.15Southern Cross Gold (ASX:SX2): -2%, AU$11.07

ASX 200ASX:COHASX:EVTASX:NXGASX:ORGASX:PDNASX:RHCASX:SX2ASX:TLXASX:TUAASX:WTC
Asia

Sun Pharmaceutical to Acquire US-Based Organon in $11.8 Billion Deal

Sun Pharmaceutical Industries (NSE:SUNPHARMA, BOM:524715) has agreed to acquire US-based Organon & Co in an all-cash deal at an enterprise valuation of $11.8 billion, according to a Monday filing to the Indian stock exchanges.Under the pact, Sun Pharmaceutical will buy all outstanding shares of Organon for $14.00 per share. It plans to fund the acquisition through a combination of available cash resources and committed financing from banks.The acquisition is estimated to boost Sun Pharmaceutical's revenues to $12.4 billion.Organon, which was spun off from Merck in 2021, specializes in women's health and biosimilars and has more than 70 products sold across 140 countries.The Organon buyout is part of Sun Pharmaceutical's strategy "of growing its Innovative Medicines business," according to Sun Pharma's statement.The transaction is subject to customary closing conditions, including receipt of required regulatory approvals andapproval by Organon stockholders.

BOM:524715NSE:SUNPHARMA